Osteonecrosis - Pipeline Review, H1 2018

Osteonecrosis - Pipeline Review, H1 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Osteonecrosis - Pipeline Review, H1 2018, provides an overview of the Osteonecrosis (Musculoskeletal Disorders) pipeline landscape.

Osteonecrosis is bone death caused by poor blood supply to the area. It is most common in the hip and shoulder, but can affect other large joints such as knee, elbow, wrist and ankle. Osteonecrosis can be caused by disease, or a severe trauma, such as a break or dislocation, that affects the blood supply to the bone. There are no symptoms in the early stages. Symptomatic treatment is available.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Osteonecrosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Osteonecrosis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteonecrosis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteonecrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 1 and 3 respectively.

Osteonecrosis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteonecrosis (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Osteonecrosis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Osteonecrosis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Osteonecrosis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Osteonecrosis (Musculoskeletal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Osteonecrosis (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Osteonecrosis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Osteonecrosis - Overview
Osteonecrosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Osteonecrosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Osteonecrosis - Companies Involved in Therapeutics Development
Bone Therapeutics SA
Enzo Biochem Inc
K-Stemcell Co Ltd
Osteonecrosis - Drug Profiles
ALLOB - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LWnt-3a - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PREOB - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize LRP for Osteonecrosis Of Jaws - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Musculoskeletal, CNS Disorders, Dermatology, Immunology, Oncology and Cardiovascular Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Osteonecrosis - Dormant Projects
Osteonecrosis - Product Development Milestones
Featured News & Press Releases
Jun 08, 2017: Bone Therapeutics: completes patient recruitment for pivotal interim analysis of Phase III Osteonecrosis trial with PREOB
Mar 09, 2017: Bone Therapeutics Completes Recruitment of 16 Patients in ALLOB PHASE I/IIA Delayed-Union Study
Oct 05, 2016: Bone Therapeutics reports positive efficacy data for the ALLOB Phase IIA spinal fusion trial
Jun 08, 2016: Bone Therapeutics demonstrates superiority of PREOB in Phase IIB osteonecrosis study presented at EULAR
May 03, 2016: Bone Therapeutics completes recruitment of its ALLOB Phase IIA spinal fusion study
Dec 04, 2014: Bone Therapeutics Authorised to Enrol Patients in the UK in Pivotal Phase III Osteonecrosis Trial with PREOB
Nov 07, 2013: Bone Therapeutics pivotal phase III osteonecrosis trial with PREOB hits a new milestone
Jan 28, 2013: Bone Therapeutics Raises 1.6m In Grant Subsidies From SRIW And Sambrinvest For Autologous Bone Cell Therapy
Oct 15, 2012: Bone Therapeutics Receives Clearance For Pivotal Phase III Osteonecrosis Trial With Preob In Europe And Treats The First Patients In Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

List of Tables
Number of Products under Development for Osteonecrosis, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Osteonecrosis - Pipeline by Bone Therapeutics SA, H1 2018
Osteonecrosis - Pipeline by Enzo Biochem Inc, H1 2018
Osteonecrosis - Pipeline by K-Stemcell Co Ltd, H1 2018
Osteonecrosis - Dormant Projects, H1 2018

List Of Figures

List of Figures
Number of Products under Development for Osteonecrosis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Osteonecrosis Global Clinical Trials Review, H1, 2018

Osteonecrosis Global Clinical Trials Review, H1, 2018GlobalDatas clinical trial report, Osteonecrosis Global Clinical Trials Review, H1, 2018 provides an overview of Osteonecrosis clinical trials scenario. This report provides top line

USD 2500 View Report

Osteonecrosis - Pipeline Review, H1 2018

Osteonecrosis - Pipeline Review, H1 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Osteonecrosis - Pipeline Review, H1 2018, provides an overview of the Osteonecrosis (Musculoskeletal Disorders) pipeline

USD 2000 View Report

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H2 2018

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1)

USD 3500 View Report

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) - Pipeline Review, H2 2018

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) - Pipeline Review, H2 2018Phosphatidylinositol 4,5

USD 3500 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available